参考文献
［1］Burger M，Catto J W F，Dalibagni G，et al.Epidemiology and risk factors of urothelial bladder cancer［J］.Eur Urol，2013，63（2）：234-241.
［2］Freedman N D，Silverman D T，Hollenbek A R，et al.Association between smoking and risk of bladder cancer among men and women［J］.JAMA，2011，306（7）：737-745.
［3］Hernandez V，Espinos E L，Dunn J，et al.Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men：a systematic review［J］.Urol Oncol，2017，35（9）：539.e17-e29.
［4］Huguet J，Crego M，Sabate S，et al.Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy：pre-cystectomy prostate involvement as a prognostic factor［J］.Eur Urol，2005，48（1）：53-59.
［5］Hussain H A，Powls T，Albers P，et al.IMvigor010：Primary analysis from a phaseⅢ randomized study of adjuvant atezolizumab（atezo）versus observation（obs）in highrisk muscle-invasive urothelial carcinoma（MIUC）［J］.J Clin Oncol，2020，38（15_suppl）：5000.
［6］Laaksonen M A，Macinnis R J，Canfell K，et al.The future burden of kidney and bladder cancers preventable by behavior modification in Australia：a pooled cohort study［J］.Int J Cancer，2020，146（3）：874-883.
［7］Lehmann J，Retz M，Wiemers C，et al.Adjuvant cisplatin plus methotrexate versus methotrexate，vinblastine，epirubicin，and cisplatin in locally advanced bladder cancer：results of a randomized，multicenter，phase Ⅲ trial（AUO-AB 05/95）［J］.J Clin Oncol，2005，23（22）：4963-4974.
［8］Ramirez D，Gupta A，Canter D，et al.Microscopichaematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer［J］.BJU Int，2016，117（5）：783-786.(https://www.daowen.com)
［9］Rentsch C A，Birkhauser F D，Biot C，et al.Bacillus calmette-guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy［J］.Eur Urol，2014，66（4）：677-688.
［10］Solsona E，Iborra I，Dumont R，et al.The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer［J］.J Urol，2000，164（3）：685-689.
［11］Soukup V，Čapoun O，Cohen D，et al.Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer：a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel systematic review［J］.Eur Urol，2017，72（5）：801-813.
［12］Tetu B.Diagnosis of urothelial carcinoma from urine［J］.Mod Pathol，2009，22（Suppl 2）：S53-S59.
［13］van Osch，Jochems S，Schooten F，et al.Quantified relations between exposure to tobacco smoking and bladder cancer risk：a meta-analysis of 89 observational studies［J］.Int J Epidemiol，2016，45（3）：857-870.
［14］Veskimae E，Neuzillet Y，Rouanne M，et al.Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy（RC）compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer［J］.BJU Int，2017，120（1）：12-24.
［15］Witjes J A，Bruins H M，Cathomas R，et al.European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer：summary of the 2020 guidelines［J］.Eur Urol，2021，79（1）：82-104.
［16］Zaghloul M S，Bouturs R，Hossieny H，et al.A prospective，randomized，placebocontrolled trial of zoledronic acid in bony metastatic bladder cancer［J］.Int J Clin Oncol，2010，15（4）：382-389.